Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
Solid organ transplantation is an important therapeutic option for children with a variety of
end stage diseases. However, the same immunosuppressive medications that are required to
prevent the child's immune system from attacking and rejecting the transplanted organ can
predispose these individuals to developing a very serious cancer that is linked to
Epstein-Barr virus (EBV).
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Clinical Trials in Organ Transplantation in Children